SCHEDULE: Millennium Entities Disclose 2.3% Stake in Enanta Pharma

Millennium Management and affiliated entities have filed an amended Schedule 13G, reporting a 2.3% beneficial ownership in Enanta Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Enanta Pharmaceuticals, Inc. Common Stock.
• As of December 31, 2025, Integrated Core Strategies (US) LLC beneficially owned 665,953 shares, representing 2.3% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially owned 670,428 shares, also representing 2.3% of the class.
• The reporting persons share voting and dispositive power over their respective reported shares.
• The securities were not acquired for the purpose of changing or influencing control of Enanta Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from the issuer or the reporting entities regarding the issuer's future performance.

Industry Context

This filing indicates a significant, though non-controlling, stake held by a prominent institutional investor group in Enanta Pharmaceuticals, a biotechnology company. Such disclosures are common for institutional investors managing diversified portfolios and reflect their positions in publicly traded companies within the pharmaceutical or biotech sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Key Dates

Keywords

Enanta Pharmaceuticals, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing